Joseph Schoeber, MD
Family Medicine · Casper, WYNPI 1740233071
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $170,700 of the $176,287 with a category attached, or 96.8%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 83.3% of it on its own, with 30 other manufacturers making up the rest. Among family medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $459.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$147K
- Shire North American Group Inc$24K
- AstraZeneca$1K
- AbbVie$1K
- GSK$633
- Lilly USA, LLC$421
- plus $2K from 25 others
What the payments were for
- Consulting fees$170,70097%
- Food & beverage$5,3603%
- Education$2270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 71 | $146,778 |
| Shire North American Group Inc | 12 | $24,000 |
| AstraZeneca | 42 | $1,141 |
| AbbVie(2 entities) | 53 | $1,074 |
| GSK | 37 | $633 |
| Lilly USA, LLC | 29 | $421 |
| Merck | 30 | $409 |
| Novo Nordisk | 28 | $336 |
| Astellas Pharma US Inc | 7 | $239 |
| Sunovion Pharmaceuticals Inc. | 18 | $136 |
| Lundbeck LLC | 7 | $134 |
| Amgen | 9 | $125 |
| Pfizer | 7 | $125 |
| Novartis | 6 | $117 |
| Boston Scientific | 3 | $93 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 1 | $68 |
| Abbott | 3 | $52 |
| Insulet Corporation | 1 | $50 |
| Axsome Therapeutics, Inc. | 1 | $48 |
| Boehringer Ingelheim | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $38 |
| Dexcom, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $21 |
| Grifols USA, LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Biogen | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$176,287 in reported general payments places this provider in the 95th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $161,634 |
| MounjaroTirzepatide | 153 | $161,417 |
| TrulicityDulaglutide | 86 | $117,561 |
| OzempicSemaglutide | 102 | $114,502 |
| FarxigaDapagliflozin Propanediol | 86 | $84,251 |
| MyrbetriqMirabegron | 82 | $59,239 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $53,400 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $41,318 |
| JardianceEmpagliflozin | 45 | $40,751 |
| JanuviaSitagliptin Phosphate | 59 | $34,539 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $23,030 |
| XareltoRivaroxaban | 25 | $21,864 |
| RexultiBrexpiprazole | 11 | $21,812 |
| LinzessLinaclotide | 23 | $14,476 |
| Dexlansoprazole DrDexlansoprazole | 19 | $11,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $421 | $278,978239 claims |
| PfizerEliquis, Premarin | $125 | $166,729203 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,141 | $132,301171 claims |
| Novo NordiskOzempic | $336 | $114,502102 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $633 | $76,430126 claims |
| Astellas Pharma US IncMyrbetriq | $239 | $59,23982 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $44 | $46,62658 claims |
| MerckJanuvia, Dulera | $409 | $39,79975 claims |
| AbbVieLinzess | $1,074 | $14,47623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Casper
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
- Jonathan BinderCasper$4K
- Sherrill FoxCasper$4K
- Taylor PedersenCasper$4K
- Tiffany SpauldingCasper$2K
- Brehan NewellCasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.